BrightSpring Earnings Call Highlights Strong Growth Momentum

BrightSpring Health Services, Inc. ((BTSG)) has held its Q1 earnings call. Read on for the main highlights of the call.

BrightSpring Health Services, Inc. struck an upbeat tone on its latest earnings call, underscoring strong revenue growth, sharply higher profitability, and improving leverage. Management balanced this optimism with a candid discussion of sizable, but well-telegraphed, headwinds from drug pricing reforms and brand-to-generic shifts, while reaffirming guidance and expressing confidence in its mitigation strategies.

Accelerating Revenue Across Core Businesses

BrightSpring reported Q1 2026 revenue of $3.6 billion, up 26% year-over-year, signaling broad-based demand across its platform. Pharmacy Solutions delivered $3.2 billion in sales, rising 25% versus last year, while Provider Services climbed 28% to $442 million, underscoring strength in both pharmacy and care delivery.

Profitability Surges With Margin Expansion

Earnings power improved even faster than the top line, with adjusted EBITDA jumping 45% to $190 million in Q1. The company’s adjusted EBITDA margin expanded by roughly 70 basis points to 5.3%, and adjusted EPS reached $0.39, demonstrating operating leverage despite ongoing investments.

Specialty and Infusion Lead Pharmacy Momentum

The standout engine was Specialty & Infusion, where revenue surged 36% to $2.6 billion and script volumes grew around 30% year-over-year. Pharmacy Solutions posted gross profit of $301 million, up 48%, and adjusted EBITDA of $169 million, up 46%, supported by strong adherence metrics and a 4.6-day time-to-first-fill.

Provider Services Benefit From Home Health Integrations

Provider Services continued to scale profitably, with gross profit of $181 million, up 35%, and adjusted EBITDA of $66 million, up 29%, for a 14.9% margin. Home Health revenue jumped 49% to $266 million, helped by acquired Amedisys and LHC branches, which added about $79 million of revenue and roughly $9 million of EBITDA in the quarter.

Operational Quality Underpins Growth Strategy

Management highlighted quality and service metrics as a competitive edge across the platform, especially in Home Health and infusion. Over 91% of Home Health branches are rated four stars or higher, timely initiation of care exceeds 99%, and patient satisfaction in infusion hits 94%, supporting retention and referral growth.

Cash Generation and Stronger Balance Sheet

Operating cash flow reached $123 million in Q1, excluding fees from the divested Community Living business, pointing to solid cash conversion. The roughly $835 million Community Living sale, with about $811 million in net proceeds before tax, helped reduce net debt to about $1.7 billion and lowered leverage to 2.27x from 2.99x.

Home & Community Pharmacy Hit by IRA and Exits

Not all segments grew, as Home & Community Pharmacy revenue declined 9% year-over-year to $527 million. Management tied this to a roughly $50 million Q1 hit from federal drug pricing reforms and a deliberate exit from uneconomic customers, with a similar revenue drag expected in each remaining quarter of 2026.

Large but Managed Industry Headwinds

The company reiterated that it faces significant full-year headwinds from policy and mix shifts, including specialty and infusion impacts and brand-to-generic conversions. In total, these factors, combined with Home & Community pressure, amount to roughly $600 million in anticipated revenue headwinds, though BrightSpring aims to offset about $15 million of related EBITDA impact.

Increased Corporate Investments to Support Growth

Corporate and SG&A costs rose in Q1, reflecting spending on IT, salesforce expansion, and other growth initiatives that management views as foundational. Executives signaled that corporate expenses will climb modestly through the year as these investments continue, trading near-term margin pressure for longer-term scale.

Tax and Financing Considerations in the Near Term

The sale of Community Living will trigger approximately $100 million in taxes expected to be paid in Q2, temporarily nudging leverage higher on a pro forma basis. Quarterly interest expense is projected around $35 million, giving investors visibility into the ongoing cost of the company’s capital structure.

Competitive and PBM Landscape Remains a Watch Point

Management acknowledged that evolving strategies by large pharmacy benefit managers, including private-label and biosimilar initiatives, could reshape channel dynamics over time. While BrightSpring sees limited direct exposure today, it framed PBM and payer behavior as an important risk factor that requires continued monitoring.

Guidance and Forward Outlook Emphasize Growth and Cash

For 2026, excluding Community Living and any not-closed deals, BrightSpring guided revenue to $14.725–$15.225 billion, implying mid-teens to high-teens growth versus 2025. Adjusted EBITDA is expected at $795–$825 million, including about $30 million from Amedisys and LHC, with annual operating cash flow of around $500 million and leverage hovering in the low-2x range even after expected Q2 taxes.

BrightSpring’s earnings call painted a picture of a company growing rapidly and improving profitability while navigating a complex policy and reimbursement backdrop. For investors, the key takeaway is a management team leaning into specialty, infusion, and home health growth drivers, using asset sales to fortify the balance sheet, and reaffirming ambitious guidance despite well-defined external headwinds.